Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

David M Dingli, Sikander Ailawadhi, Peter Leif Bergsagel, Francis K. Buadi, Angela Dispenzieri, Rafael Fonseca, Morie Gertz, Wilson Gonsalves, Susan R. Hayman, Prashant Kapoor, Taxiarchis Kourelis, Shaji K Kumar, Robert A. Kyle, Martha Lacy, Nelson Leung, Yi Lin, John A. Lust, Joseph R Mikhael, Craig B. Reeder, Vivek RoyStephen J Russell, Taimur Sher, Alexander Keith Stewart, Rahma Warsame, Stephen R. Zeldenrust, S Vincent Rajkumar, Asher A Chanan Khan

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.

Original languageEnglish (US)
Pages (from-to)578-598
Number of pages21
JournalMayo Clinic Proceedings
Volume92
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Multiple Myeloma
Guidelines
Recurrence
Patient Care
Therapeutics
Decision Trees
Life Expectancy
Clone Cells
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9bfd9fa262a840e9ace8aa8853c78db5,
title = "Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy",
abstract = "Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.",
author = "Dingli, {David M} and Sikander Ailawadhi and Bergsagel, {Peter Leif} and Buadi, {Francis K.} and Angela Dispenzieri and Rafael Fonseca and Morie Gertz and Wilson Gonsalves and Hayman, {Susan R.} and Prashant Kapoor and Taxiarchis Kourelis and Kumar, {Shaji K} and Kyle, {Robert A.} and Martha Lacy and Nelson Leung and Yi Lin and Lust, {John A.} and Mikhael, {Joseph R} and Reeder, {Craig B.} and Vivek Roy and Russell, {Stephen J} and Taimur Sher and Stewart, {Alexander Keith} and Rahma Warsame and Zeldenrust, {Stephen R.} and Rajkumar, {S Vincent} and {Chanan Khan}, {Asher A}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.mayocp.2017.01.003",
language = "English (US)",
volume = "92",
pages = "578--598",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Therapy for Relapsed Multiple Myeloma

T2 - Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

AU - Dingli, David M

AU - Ailawadhi, Sikander

AU - Bergsagel, Peter Leif

AU - Buadi, Francis K.

AU - Dispenzieri, Angela

AU - Fonseca, Rafael

AU - Gertz, Morie

AU - Gonsalves, Wilson

AU - Hayman, Susan R.

AU - Kapoor, Prashant

AU - Kourelis, Taxiarchis

AU - Kumar, Shaji K

AU - Kyle, Robert A.

AU - Lacy, Martha

AU - Leung, Nelson

AU - Lin, Yi

AU - Lust, John A.

AU - Mikhael, Joseph R

AU - Reeder, Craig B.

AU - Roy, Vivek

AU - Russell, Stephen J

AU - Sher, Taimur

AU - Stewart, Alexander Keith

AU - Warsame, Rahma

AU - Zeldenrust, Stephen R.

AU - Rajkumar, S Vincent

AU - Chanan Khan, Asher A

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.

AB - Life expectancy in patients with multiple myeloma is increasing because of the availability of an increasing number of novel agents with various mechanisms of action against the disease. However, the disease remains incurable in most patients because of the emergence of resistant clones, leading to repeated relapses of the disease. In 2015, 5 novel agents were approved for therapy for relapsed multiple myeloma. This surfeit of novel agents renders management of relapsed multiple myeloma more complex because of the occurrence of multiple relapses, the risk of cumulative and emergent toxicity from previous therapies, as well as evolution of the disease during therapy. A group of physicians at Mayo Clinic with expertise in the care of patients with multiple myeloma regularly evaluates the evolving literature on the biology and therapy for multiple myeloma and issues guidelines on the optimal care of patients with this disease. In this article, the latest recommendations on the diagnostic evaluation of relapsed multiple myeloma and decision trees on how to treat patients at various stages of their relapse (off study) are provided together with the evidence to support them.

UR - http://www.scopus.com/inward/record.url?scp=85014749660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014749660&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2017.01.003

DO - 10.1016/j.mayocp.2017.01.003

M3 - Review article

C2 - 28291589

AN - SCOPUS:85014749660

VL - 92

SP - 578

EP - 598

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -